Canaccord Genuity Maintains Buy on AngioDynamics, Raises Price Target to $20

AngioDynamics, Inc.

AngioDynamics, Inc.

ANGO

0.00

Canaccord Genuity analyst John Young maintains AngioDynamics (NASDAQ: ANGO) with a Buy and raises the price target from $16 to $20.